Business
Rapid information on patient response to therapies
Rapid information on patient response to therapies.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2925G\n Angle PLC\n 29 March 2022\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 29 March 2022\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS\n \n \n \n \n \n Existing chemotherapies, such as vinorelbine, may selectively target and reduce the metastatic potential of CTCs\n \n \n \n \n \n Detecting a reduction of microtentacles, that enable the spread of cancer, on live CTCs indicates a positive response to therapy\n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, \n is pleased to announce that the University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute, Baltimore, Maryland, USA, has published results of work undertaken in preclinical models of triple-negative breast cancer (TNBC), showing that isolation of live circulating tumour cells (CTCs) from a simple blood draw, using the Parsortix® system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth. \n \n \n \n \n \n The research team has previously demonstrated that breast cancer cells circulating in the blood form unique microtentacles that enable the spread and formation of tumours at secondary sites. Microtentacles are supported by microtubules, which are the target for many FDA-approved chemotherapy drugs, such as vinorelbine used in this study.\n \n \n \n \n \n Using preclinical TNBC models, the researchers showed that vinorelbine treatment increased the time taken for the cancer to spread from 8 to 30 weeks. However, a 24-hour vinorelbine treatment had little effect on the primary tumour development and survival, indicating selective targeting of the metastatic potential of CTCs through microtubule disruption. The results of this study indicate that CTCs demonstrate specific features which can be leveraged to reveal the anti-metastatic capabilities of vinorelbine and potentially other existing FDA-approved therapies.\n \n \n \n \n \n In the US, breast cancer is the most frequently diagnosed cancer in women with 287,000 new cases expected in 2022, accounting for 31% ...